The stock price of Lineage Cell Therapeutics Inc (AMEX: LCTX) has jumped by 5.59% compared to previous close of $0.98. Despite this, the company has seen a gain of 15.85% in its stock price over the last five trading days. businesswire.com reported 2025-06-23 that CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (.
Is It Worth Investing in Lineage Cell Therapeutics Inc (AMEX: LCTX) Right Now?
Moreover, the 36-month beta value for LCTX is 1.65. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for LCTX is 227.36M and currently, short sellers hold a 12.64% of that float. On July 09, 2025, LCTX’s average trading volume was 2.20M shares.
LCTX’s Market Performance
The stock of Lineage Cell Therapeutics Inc (LCTX) has seen a 15.85% increase in the past week, with a 54.03% rise in the past month, and a 159.87% gain in the past quarter. The volatility ratio for the week is 10.42%, and the volatility levels for the past 30 days are at 12.50% for LCTX. The simple moving average for the past 20 days is 13.25% for LCTX’s stock, with a 57.43% simple moving average for the past 200 days.
Analysts’ Opinion of LCTX
Many brokerage firms have already submitted their reports for LCTX stocks, with Craig Hallum repeating the rating for LCTX by listing it as a “Buy.” The predicted price for LCTX in the upcoming period, according to Craig Hallum is $4 based on the research report published on August 20, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see LCTX reach a price target of $5. The rating they have provided for LCTX stocks is “Outperform” according to the report published on November 02nd, 2022.
B. Riley Securities gave a rating of “Buy” to LCTX, setting the target price at $4 in the report published on June 14th of the previous year.
LCTX Trading at 48.94% from the 50-Day Moving Average
After a stumble in the market that brought LCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.57% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LCTX starting from BROADWOOD PARTNERS, L.P., who purchase 7,894,737 shares at the price of $0.76 back on Jan 27 ’25. After this action, BROADWOOD PARTNERS, L.P. now owns 49,560,992 shares of Lineage Cell Therapeutics Inc, valued at $6,000,000 using the latest closing price.
Howe Jill Ann, the Chief Financial Officer of Lineage Cell Therapeutics Inc, purchase 15,000 shares at $0.59 during a trade that took place back on Nov 26 ’24, which means that Howe Jill Ann is holding 25,500 shares at $8,850 based on the most recent closing price.
Stock Fundamentals for LCTX
Current profitability levels for the company are sitting at:
- -2.23 for the present operating margin
- 0.97 for the gross margin
The net margin for Lineage Cell Therapeutics Inc stands at -1.7. The total capital return value is set at -0.22. Equity return is now at value -21.40, with -14.72 for asset returns.
Based on Lineage Cell Therapeutics Inc (LCTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -9.89.
Currently, EBITDA for the company is -20.87 million with net debt to EBITDA at 2.19. When we switch over and look at the enterprise to sales, we see a ratio of 20.19. The receivables turnover for the company is 44.87for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.82.
Conclusion
To wrap up, the performance of Lineage Cell Therapeutics Inc (LCTX) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
